More on IMGN
Data
Financials
Upcoming Events
News
Click line-items for a historical chart and %
| Research and development support | 1.35M |
| License and milestone fees | 76K |
| Clinical materials reimbursement | 46K |
| Total revenues | 7.66M |
| Research and development | 32.91M |
| General and administrative | 9.46M |
| Total operating expenses | 46.5M |
| Loss from operations | -38.84M |
| Other (expense) income, net | 129K |
| Loss before provision for income taxes | |
| Net loss | -44.73M |
| Basic and diluted net loss per common share (in dollars per share) | -0.51 |
| Basic weighted average common shares outstanding (in shares) | |
| Diluted weighted average common shares outstanding (in shares) | |
Entities mentioned with IMGN
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Jefferies & Co | View Related Stories »
- Canaccord Genuity | View Related Stories »
- Pre Market Movers | View Related Stories »
- Goldman Sachs | View Related Stories »
- Show More...
